Connectivity Healthcare
Photo Source:

AUM Cardiovascular, the maker of a handheld device with advanced analytics to help rule out coronary artery blockages, uses Internet of Things (IoT) global connectivity provided by AT&T to deliver diagnostic test results to patients in about 10 minutes. Undetected, severe blockage can lead to a heart attack – and in some instances, sudden death.

The CADence device, designed and manufactured by AUM Cardiovascular, is a quick, noninvasive, no needle, zero-radiation test. The device uses sophisticated acoustic detection and analysis — a very exciting new method that looks for Coronary Artery Disease (CAD) risk factors in patients by the sound of blood flow in the coronary arteries.

The CADence handheld device collects heart sound data on 4 locations of the patient’s chest. A tablet with an app custom built to work with AT&T’s wireless services receives data from the device. The AT&T Global SIM card sends the data in a highly secure manner to AUM’s secure server for acoustic analysis.

Within about 10 minutes of the data upload, the clinician receives the results via email. The entire process takes about 20 minutes.

The process, typically quick and painless for patients, can be performed in the doctor’s office, hospital, home or virtually anywhere cellular coverage is available. CADence’s convenience and ease-of-use makes it useful for a wide variety of clinicians including cardiologists, family and internal medicine doctors, nurse practitioners, nurses and certified medical assistants.

“My husband, Rob, fell victim to undetected coronary artery disease at the age of 41. I know firsthand the devastation this disease can cause,” said AUM Cardiovascular Founder and CEO, Marie Johnson, PhD. “We are using the latest technology and AT&T global connectivity to quickly and easily determine if CAD risk factors are present. We hope to prevent tragedy for other families.”

CADence is currently available in Germany. The company is looking to expand to other EU countries andAustralia later this year, and Canada and the Philippines in 2017.

CADence is currently under review by the FDA for clearance in the U.S. CADence is expected to be in the U.S. market by the end of 2017, pending FDA approval.

For more information please visit